summary

The following information from the DARZALEX PRESCRIBING INFORMATION and MEDICATION GUIDE may be helpful in addressing your question¹:

• DARZALEX in combination with bortezomib, thalidomide and dexamethasone (VTd) is indicated in adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (ASCT).
• The recommended dose of DARZALEX is 16 mg/kg of actual body weight administered as an intravenous (IV) infusion.
• The recommended dosing schedule of DARZALEX when administered in combination with VTd is summarized in the Figure: Dosing Schedule for DARZALEX in Combination With VTd.

• DARZALEX may be given alone or together with other medicines used to treat multiple myeloma.
• Your healthcare provider will decide the time between doses as well as how many treatments you will receive.
• Your healthcare provider will give you medicines before each dose of DARZALEX and after each dose of DARZALEX to help reduce the risk of infusion-related reactions.
• If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.  

additional information

This information is provided ONLY in response to your request and is not intended as medical advice, to promote the use of our product, or suggest using it in any manner other than as described in the PRESCRIBING INFORMATION. All decisions regarding your medical treatment should be made with your healthcare professional(s). Please contact your healthcare professional(s) to discuss the information in this response.

Please refer to the attached full PRESCRIBING INFORMATION and the PATIENT MEDICATION GUIDE for DARZALEX.¹